MAPK1 and neoplasm: Hirata et al. demonstrated that after treatment with the BRAFi PLX4720, the MAF-derived matrix abrogates the anti-tumor effects of BRAFi by leading to ERK reactivation and cell survival in melanoma cells via adhesion-dependent β1-integrin-FAK-Src signalling.